Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
CJC-1295 is a longer-acting fragment of growth-hormone-releasing hormone. Ipamorelin is a separate peptide that mimics ghrelin to prompt a growth-hormone pulse. Clinics often combine them so the two signals stack. Both are injections.
The pair is heavily promoted in fitness and anti-aging circles for body composition and recovery. They are also among the peptides the FDA has flagged in its compounding review, which keeps them in the news.
| Claim | Strongest evidence |
|---|---|
| Raises the body's growth hormone and IGF-1 | B Human open-label / small study |
| Body composition or recovery benefit in healthy adults | C Animal |
| Anti-aging outcomes | E Anecdote |
Neither CJC-1295 nor Ipamorelin is an FDA-approved drug. They are sold as compounded or research peptides. The FDA has raised safety and characterization concerns about CJC-1295 in its compounding review and has not placed it on the 503A list. Use requires a licensed provider, and quality is not FDA-reviewed.
Pricing is set by the compounding pharmacy and the protocol, so it varies more than the branded telehealth peptides. It is commonly bundled as a monthly GH-peptide program. The numbers below are observed and approximate, not a single published list price.
| Where | Observed price | Model |
|---|---|---|
| Compounded monthly program (observed, approximate) | roughly $100 to $300 / month | Varies by pharmacy, dose, and whether it is stacked |
| Provider visit and labs | billed separately | Often required before a compounding pharmacy will dispense |
Human outcome data is limited and mostly short-term. Reported effects include water retention, injection-site reactions, and headache. Because these are compounded or research peptides, purity and dosing accuracy are not FDA-reviewed. The FDA has flagged safety and characterization gaps for CJC-1295.
Pricing is set by the compounding pharmacy and protocol, so it varies. Observed monthly programs are roughly in the low hundreds of dollars, often about 100 to 300 dollars, plus separate visit and lab fees.
No. Neither is FDA-approved. They are compounded or research peptides, and the FDA has raised safety concerns about CJC-1295 in its compounding review.
They act through two different signals, so clinics stack them to prompt a larger growth-hormone pulse than either alone. This is a marketing and protocol choice, not an approved combination.
One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.